## **Rohit Bose**

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5642879/publications.pdf

Version: 2024-02-01

840585 996849 2,488 17 11 15 h-index citations g-index papers 18 18 18 3834 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Regulation of the Polarity Protein Par6 by TGFÂ Receptors Controls Epithelial Cell Plasticity. Science, 2005, 307, 1603-1609.	6.0	824
2	High-Throughput Mapping of a Dynamic Signaling Network in Mammalian Cells. Science, 2005, 307, 1621-1625.	6.0	651
3	Regulation of Planar Cell Polarity by Smurf Ubiquitin Ligases. Cell, 2009, 137, 295-307.	13.5	289
4	The DNA methylation landscape of advanced prostate cancer. Nature Genetics, 2020, 52, 778-789.	9.4	198
5	FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes. Nature, 2019, 571, 408-412.	13.7	163
6	A role for the TGFÂ-Par6 polarity pathway in breast cancer progression. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 14028-14033.	3.3	115
7	ERF mutations reveal a balance of ETS factors controlling prostate oncogenesis. Nature, 2017, 546, 671-675.	13.7	70
8	Regulation of Par6 by extracellular signals. Current Opinion in Cell Biology, 2006, 18, 206-212.	2.6	66
9	Degradation of RhoA by Smurf1 Ubiquitin Ligase. Methods in Enzymology, 2006, 406, 437-447.	0.4	61
10	Genomic Alteration Burden in Advanced Prostate Cancer and Therapeutic Implications. Frontiers in Oncology, 2019, 9, 1287.	1.3	22
11	Spectroscopic characterization by laser flash photolysis of electrophilic intermediates derived from 4-aminostilbenes. Stilbene "nitrenium―ions and quinone methide imines â€. Journal of the Chemical Society Perkin Transactions II, 1999, , 1591-1600.	0.9	17
12	TGFÎ <sup>2</sup> Signal Transduction. , 2010, , 521-532.		7
13	Investigation of a frequently mutated transcriptional repressor in prostate cancer, in particular its role in modulating androgen signaling and its effects on TMPRSS2-ERG dependent tumor maintenance Journal of Clinical Oncology, 2016, 34, 274-274.	0.8	1
14	Trafficking of Serine/Threonine Kinase Receptors and Smad Activation., 2006, , 177-191.		1
15	c15-153: Randomized phase IB/II study of enzalutamide with and without ribociclib in patients with metastatic castrate resistant, chemotherapy naĀ ve prostate cancer that retains RB expression Journal of Clinical Oncology, 2018, 36, TPS384-TPS384.	0.8	1
16	Mobile Audio Recording Technology to Promote Informed Decision Making in Advanced Prostate Cancer. JCO Oncology Practice, 2021, , OP2100480.	1.4	1
17	Abstract LB-018: Loss of function mutations of an ETS repressor expand the ETS positive subset of prostate cancer., 2016,,.		О